Skip to main content
Clinical Trials/NCT03947957
NCT03947957
Active, not recruiting
Not Applicable

Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis

University Hospital, Brest11 sites in 1 country70 target enrollmentOctober 2, 2020

Overview

Phase
Not Applicable
Intervention
collection of expectoration, stools and blood
Conditions
Cystic Fibrosis
Sponsor
University Hospital, Brest
Enrollment
70
Locations
11
Primary Endpoint
Presence of P. aeruginosa in bacterial sputum cultures collected at 36 months of age
Status
Active, not recruiting
Last Updated
2 months ago

Overview

Brief Summary

The objective of this study is to evaluate the predictive nature of the biomarker Porphyromonas catoniae measured at the age of 12 months in the occurrence of colonization with Pseudomonas aeruginosa at 36 months of age in children with cystic fibrosis.

Detailed Description

This is a multicentric study in 3 phases: * Pre-inclusion: at the first visit to the CRCM (support for a positive screening confirmed by sweat test and genotyping CFTR) * Inclusion: possible between the 2nd visit to the CRCM (about 2 months old) and the 6th month * Follow-up: up to 36 months old. The pace of visits will be based on the usual follow-up rate of CF infants The clinical data as well as samples (expectorations, stools) will be collected on a monthly basis up to 6 months old and then every 2 months until one year old and finally quarterly until 3 years old. * Tracheo-bronchial secretions will be collected at the CRCM * Stools samples will be carried out by the parents prior to consultation with the CRCM * A blood collection will be carried out annually in an annual report.

Registry
clinicaltrials.gov
Start Date
October 2, 2020
End Date
July 1, 2026
Last Updated
2 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Infants aged 6 months maximum at inclusion with a confirmed diagnosis of cystic fibrosis in its classical form (positive sweat test and/or two mutations of the CFTR gene from class I to III) -Children free from any antecedent of colonization to P. aeruginosa at the time of inclusion (certified by the microbiological history supplemented by a molecular test by qPCR according to the diagram of Le gal et al., 2013)---
  • Affiliation to the social security system
  • Consent signed by the holders of parental authority or the sole parent holding parental authority / and "oral" agreement of the second holder

Exclusion Criteria

  • Severe acute illness (other than cystic fibrosis) ongoing, or requiring surgery
  • Children unable to undergo the tests required by the protocol
  • Children whose parent(s) is/are minors
  • Children whose legal guardians do not have sufficient command of the French language
  • Children under exclusive parenteral nutrition
  • Refusal to participate in the study

Arms & Interventions

collection of expectoration, stools and blood

Intervention: collection of expectoration, stools and blood

Outcomes

Primary Outcomes

Presence of P. aeruginosa in bacterial sputum cultures collected at 36 months of age

Time Frame: 36 months

positive or negative

Secondary Outcomes

  • Absolute amount of P. aeruginosa at different sampling times.(36 months)
  • Level of dysbiosis(36 months)
  • Absolute amount of P. catoniae in respiratory secretions at different sampling times and Delta between 12, 24 and 36 months.(36 months)
  • Absolute amount of P. catoniae in stool at different sampling times and Delta between 12, 24 and 36 months.(36 months)
  • Number, diversity, and quality of antibiotic resistance genes(36 Months)
  • Levels of blood metabolites(36 Months)
  • Pulmonary concentration of inflammatory markers(36 months)
  • Constitutional SNPs(36 Months)
  • Breastfeeding at each visit(36 Months)
  • Dietary diversification at each visit(36 Months)
  • Treatments received at each visit(36 Months)

Study Sites (11)

Loading locations...

Similar Trials